Avidity Biosciences, Inc.

Avidity Biosciences, Inc. | 3,050 followers on LinkedIn. At Avidity, we are developing a new class of oligonucleotide-based therapies. | At Avidity, we are developing a new class of oligonucleotide-based therapies. We utilize our proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. We hope that our AOC therapies can treat a wide range of serious diseases and our initial focus is on muscle diseases.